FDA approves Lilly's Foundayo pill at $149 a month self-pay

The FDA approved Eli Lilly's orforglipron, sold as Foundayo, on April 1. It follows Novo Nordisk's Wegovy tablet, approved for weight management in December, and Lilly describes it as the only GLP-1 pill for weight loss that can be taken at any time of day without restrictions on food and water. Lilly has set a self-pay price starting at $149 a month — below the monthly price of most injectable GLP-1 programs in our price database.

What happened

Lilly announced on April 1 that the FDA "approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems." The release describes the product as "a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake." Orforglipron was discovered by Chugai Pharmaceutical and licensed by Lilly in 2018.

Three prices appear in the release, and they are the part of this story that changes anyone's arithmetic. "Individuals opting for self-pay can access Foundayo starting at $149 per month for the lowest dose." "Eligible people with commercial insurance may pay as little as $25 per month with the Foundayo savings card." And "eligible Medicare Part D individuals may be able to get Foundayo for $50 per month, beginning as soon as July 1, 2026." The $149 figure is a floor, not a flat rate: STAT reported on April 1 that Lilly "will sell the pill at up to $299 a month if patients continually renew their prescription," and that Novo Nordisk "launched the Wegovy pill at a cash price of up to $299 a month" before this approval.

On distribution, the release says Foundayo "will be available via LillyDirect®, with prescriptions accepted immediately and shipping beginning April 6, followed shortly after by broad availability through U.S. retail pharmacies and telehealth providers." As of April 3, that second stage had not happened, and we had found no announcement from any brand in our database that it carries Foundayo, which is why this article lists no affected brands.

The prescribing information carries a boxed warning. Its heading, in the label Lilly published with the approval, reads "WARNING: RISK OF THYROID C-CELL TUMORS," and the label directs readers to "See full prescribing information for complete boxed warning." The safety summary in Lilly's release states: "Foundayo may cause tumors in the thyroid, including thyroid cancer." We are quoting those words and not adding to them. The label and your prescriber are the places to take that question.

Why it matters

$149 a month lands underneath almost everything we track. In our price database as it stands now, not as it stood in April, 55 of the 67 semaglutide and tirzepatide weight-loss plans that are not oral tablets list a starting price above $149 a month. Some of that gap is structural — several of those plans bundle clinician visits, and a few include labs — but the bundle rarely explains a difference of a hundred dollars or more. A manufacturer selling direct, at a floor price below the cash market it is entering, is a different kind of pressure than one compounder undercutting another.

We should be straight about what we do not yet have. Orforglipron has no entry in our medication library and no cost guide, because until April 1 there was nothing to price. We are building both. In the meantime the closest reference points we hold are the semaglutide cost guide and the tirzepatide medication page, and our price tracker was set to pick up Foundayo as soon as a brand we score listed it.

This also lands 25 days after Hims & Hers dropped compounded GLP-1s for a branded supply deal and named no replacement price. The pattern is consistent: the cheap end of the weight-loss market is moving from compounders to manufacturers, and the manufacturers are setting the number. Our Hims & Hers versus Ro comparison shows the two largest platforms we score sitting on branded supply agreements with the two companies now competing on pill prices.

Here is what the same two brands charge today for injectable tirzepatide, live from our database:

One caution on comparing those rows to $149. A telehealth platform's price usually includes a clinician; Lilly's self-pay price is the medicine. Our true-cost calculator exists for exactly this, and it is worth running before treating the headline numbers as like-for-like.

What this means for patients

• $149 a month is the lowest strength at self-pay through LillyDirect, per Lilly's April 1 release. It is a starting figure, not the price at every strength, and STAT reports a ceiling of $299 a month tied to continually renewing the prescription.
• If you have commercial insurance, the savings-card figure Lilly names is as low as $25 a month. Eligibility rules are Lilly's, not your telehealth provider's — check them on the manufacturer's page before you assume the number applies to you.
• Medicare Part D at $50 a month is dated "as soon as July 1, 2026" in Lilly's release. It is not available now.
• As of April 3, we had not found any telehealth brand we score saying it will carry Foundayo. Lilly's release points to retail pharmacies and telehealth providers "shortly after" April 6, with no named partners and no date. If a platform tells you otherwise this week, ask it to show you the price in writing.
• The label carries a boxed warning. Read it, and take any question about it to a prescriber rather than to a marketing page.
• If you are on an injectable program now, nothing about this approval changes your current plan or price. Do not change or stop a medication over a news story; ask your prescriber whether a different option is appropriate for you.